
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
α-sarcoglycan CRISPR/Cas9 KO Plasmid (h) | sc-403837 | 20 µg | $397.00 |
SGCA encodes human α-sarcoglycan, a core component of the sarcoglycan subcomplex within the dystrophin-associated glycoprotein complex that stabilizes the muscle cell membrane during contraction. By linking the extracellular matrix to the cortical cytoskeleton, α-sarcoglycan supports sarcolemmal integrity, mechanotransduction, and organization of membrane microdomains involved in muscle homeostasis. Disruption of SGCA perturbs dystrophin complex assembly, increases susceptibility to contraction-induced damage, and alters downstream stress and inflammatory signaling in skeletal and cardiac muscle. Loss-of-function variants are associated with limb-girdle muscular dystrophy phenotypes, making SGCA a widely used target for modeling muscle membrane instability and related pathways.
α-sarcoglycan CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SGCA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SGCA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SGCA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish α-sarcoglycan protein expression.
This CRISPR knockout system enables efficient generation of SGCA-deficient cell models for investigation of α-sarcoglycan signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.